RNA Interference News and Research

RSS

Immunomedics develops E1-L-thP1 protein complex for targeted delivery of siRNAs to diverse solid cancers

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported the development of a novel protein complex, designated as E1-L-thP1, for targeted delivery of small interfering ribonucleic acids (siRNAs) to diverse solid cancers.

19 Apr 2010

Silence Therapeutics reorganizes resources following Intradigm merger

Silence Therapeutics plc announces that the Company is executing a strategic plan designed to optimally organize its resources following its recent merger with Intradigm Corporation. Moving forward, all research activities related to Silence's novel RNA interference (RNAi) therapeutic platforms, including technologies that have emerged from both Silence and Intradigm, will take place at the Company's Berlin location.

13 Apr 2010

RXi Pharmaceuticals, miRagen Therapeutics enter into research collaboration

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference, and miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA -based therapeutics for cardiovascular and muscle disease, announced today that they have entered into a research collaboration.

13 Apr 2010

RXi Pharmaceuticals, Mirna Therapeutics form microRNA research collaboration

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced today that it has entered into a research collaboration with Mirna Therapeutics (Austin, TX), to determine the utility of combining RXi's proprietary rxRNA™ technology with Mirna's microRNA mimics as potential therapeutics in oncology. The parties will each contribute technology and resources to the collaboration to generate and evaluate novel microRNA compounds.

12 Apr 2010

Scientists discover how mechanical stress promotes new bone growth

For osteoporosis patients unable to exercise, help may be on the way. That's because scientists have discovered precisely how mechanical stress, such as exercise, promotes new bone growth. This opens the door to entirely new therapies that can trick bones into thinking they are getting a workout. The research report describing this advance is published online in The FASEB Journal.

8 Apr 2010

Officials of Kylin Therapeutics receive an issued patent from USPTO

Officials of Kylin Therapeutics Inc., a leading RNAi company, announced this week that they received an issued patent from the U.S. Patent and Trademark Office.

7 Apr 2010

MDA, FFSHR award $200,000 grant for developing FSH dystrophy therapy

The Muscular Dystrophy Association (MDA), headquartered in Tucson, Ariz., and Friends of FSH Research (FFSHR), based in Kirkland, Wash., has jointly awarded a two-year, $200,000 grant to Dr. Joel Chamberlain, a research assistant professor of medical genetics at the University of Washington. The grant, equally funded by the two organizations, will enable the laboratory led by Dr. Chamberlain to study RNA interference as an investigative and therapeutic tool for facioscapulohumeral muscular dystrophy.

7 Apr 2010

RXi Pharmaceuticals, TransDerm collaborate on study of RXi's proprietary compounds in dermatology applications

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), and TransDerm, Inc., a biopharmaceutical company developing nucleic acid skin delivery technologies and therapeutics for skin disorders, announced today that they will collaborate on studying the potential utility of RXi's proprietary compounds in dermatology models.

7 Apr 2010

RXi Pharmaceuticals reports net loss of 28% for 2009

31 Mar 2010

Japanese Patent Office grants Alnylam Pharmaceuticals' claims in second patent application for Tuschl II

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the Japanese Patent Office has granted claims in a second patent application (JP Application Number 2006-317758) for the Tuschl II patent series, entitled "RNA Interference Mediating Small RNA Molecules." In May 2008, the Japanese Patent Office granted a related set of claims in the Tuschl II patent series (JP 4 095 895).

31 Mar 2010

StockPreacher.com releases investment report on MDRNA

StockPreacher.com announces an investment report featuring drug developer MDRNA Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

30 Mar 2010

Silence Therapeutics, Dainippon Sumitomo Pharma announce expansion of siRNA delivery collaboration

Silence Therapeutics plc today announced that the company and Dainippon Sumitomo Pharma Co., Ltd. have agreed to an expansion of their ongoing small interfering RNA (siRNA) delivery collaboration. Under this collaboration, which was originally entered into in August 2009, the companies are leveraging Silence's proprietary siRNA molecules and multiple lipid delivery and targeting technologies to demonstrate functional delivery of RNA interference (RNAi) therapeutics to specific disease targets in the body.

30 Mar 2010

RXi Pharmaceuticals to present advances in RNAi therapeutics at 3rd International Scar Club Meeting

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced that Pamela Pavco, Ph.D., Vice President of Pharmaceutical Development, will be presenting at the 3rd International Scar Club Meeting in Montpellier, France on March 26, 2010.

26 Mar 2010

FIMM to launch cell microarray screening research program utilizing Aushon 2470 Arrayer technology

Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis announced today that the Institute for Molecular Medicine Finland will launch a cell microarray screening research program utilizing the Aushon 2470 Arrayer technology.

26 Mar 2010

New experiments may hold clues for controlling cancer

A protein discovered in fruit fly eyes has brought a Johns Hopkins team closer to understanding how the human heart and other organs automatically "right size" themselves, a piece of information that may hold clues to controlling cancer.

26 Mar 2010

RXi Pharmaceuticals obtains commitments to purchase 2.7M shares of common stock at $6.00 per share

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference, announced today that it has obtained commitments from several investors to purchase 2.7 million shares of its common stock at $6.00 per share and warrants to purchase 540,000 shares of its common stock for gross proceeds of $16.2 million.

26 Mar 2010

How does a heart know when it's big enough?

25 Mar 2010

Investment report on Arrowhead Research

BeaconEquity.com announces an investment report featuring Arrowhead Research Corp. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

23 Mar 2010

Calando Pharmaceuticals demonstrates first targeted siRNA-containing nanoparticle delivery to tumors

Arrowhead Research Corporation today announced that the clinical trial being conducted by majority-owned subsidiary, Calando Pharmaceuticals, Inc., has demonstrated systemic delivery of siRNA and the successful “silencing” of a widely recognized cancer gene via RNA interference (RNAi) in humans.

22 Mar 2010

Nanotechnology weapons for cancer

US Researchers have come up with new nanoparticle robots that are essentially a tiny army that can travel in the blood till they reach the cancers and then tweak some important cancer causing genes that can cure the cancer.

22 Mar 2010

RNA Interference News and Research

Immunomedics develops E1-L-thP1 protein complex for targeted delivery of siRNAs to diverse solid cancers

Silence Therapeutics reorganizes resources following Intradigm merger

RXi Pharmaceuticals, miRagen Therapeutics enter into research collaboration

RXi Pharmaceuticals, Mirna Therapeutics form microRNA research collaboration

Scientists discover how mechanical stress promotes new bone growth

Officials of Kylin Therapeutics receive an issued patent from USPTO

MDA, FFSHR award $200,000 grant for developing FSH dystrophy therapy

RXi Pharmaceuticals, TransDerm collaborate on study of RXi's proprietary compounds in dermatology applications

RXi Pharmaceuticals reports net loss of 28% for 2009

Japanese Patent Office grants Alnylam Pharmaceuticals' claims in second patent application for Tuschl II

StockPreacher.com releases investment report on MDRNA

Silence Therapeutics, Dainippon Sumitomo Pharma announce expansion of siRNA delivery collaboration

RXi Pharmaceuticals to present advances in RNAi therapeutics at 3rd International Scar Club Meeting

FIMM to launch cell microarray screening research program utilizing Aushon 2470 Arrayer technology

New experiments may hold clues for controlling cancer

RXi Pharmaceuticals obtains commitments to purchase 2.7M shares of common stock at $6.00 per share

How does a heart know when it's big enough?

Investment report on Arrowhead Research

Calando Pharmaceuticals demonstrates first targeted siRNA-containing nanoparticle delivery to tumors

Nanotechnology weapons for cancer

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News